TREATMENT EDUCATION LIBRARY
Cancer Treatment Explained / Targeted Therapy
Targeted Cancer Therapy — A Complete Patient Guide
The right target. The right context. A treatment plan built around cancer biology.
Understand biomarkers, treatment choices, side effects and resistance. Use this guide with your oncology team’s advice; medicine examples are not individual recommendations.
Medical Content & Review
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
Start with what matters now: Urgent warning signs · Testing · Side effects · Resistance · Patient FAQs
In this guide
Understanding targeted therapy
- What is targeted cancer therapy?
- How do cancer cells grow?
- Targeted therapy versus chemotherapy versus immunotherapy
- Main types of targeted cancer medicines
Biomarkers and testing
- Why is molecular testing important?
- What is an actionable mutation?
- What if molecular testing is negative?
Important pathways and medicines
- EGFR-targeted therapy
- ALK-targeted therapy
- ROS1-targeted therapy
- HER2-targeted therapy
- BRAF and MEK inhibitors
- KRAS-targeted therapy
- PARP inhibitors
- CDK4/6 inhibitors
- Anti-angiogenic targeted therapy
- Other important targeted pathways
The patient experience
- How is targeted therapy given?
- What happens before starting targeted therapy?
- Common side effects
- EGFR inhibitor skin toxicity
- Diarrhoea during targeted therapy
- Serious warning signs
Response and resistance
- How do doctors know targeted therapy is working?
- Why does targeted therapy sometimes stop working?
- What happens when targeted therapy stops working?
- Can targeted therapy cure cancer?
- How long is targeted therapy continued?
Practical questions
- Diet, supplements and targeted therapy
- Work, travel and exercise
- Fertility, pregnancy and breastfeeding
- Targeted therapy in older patients
- Financial considerations
Myths, FAQs and your next conversation
- Targeted therapy myths
- Frequently asked questions
- Questions to ask your oncologist
- A final message for patients and families
Medical review and references
What is targeted cancer therapy?
Targeted therapy is a broad family of medicines that interfere with particular proteins, signals or processes that a cancer uses to grow and survive. Some block an abnormal growth switch; others interfere with DNA repair, cell division or the formation of tumour blood vessels. The target can also exist in healthy tissue, which helps explain side effects.
A cancer may become especially dependent on one altered protein. Blocking that dependency can sometimes produce substantial shrinkage and prolonged control. However, a molecular match does not guarantee a response, and the same alteration may behave differently in different cancers. Some treatments contribute to curative-intent care; others aim to control advanced disease and preserve quality of life.
Conventional chemotherapy commonly damages DNA or disrupts cell division. Targeted medicines focus on a more specific biological process, but the categories can overlap. They may be used together. Targeted treatment is neither suitable for every cancer nor automatically less toxic.
Key fact: Not every targeted medicine requires an actionable mutation test. Selection may instead use protein expression, hormone-receptor status, the cancer diagnosis or a proven clinical indication—as with many anti-angiogenic treatments.
How do cancer cells grow?
- DNA and genes
- DNA stores cellular instructions. Genes are sections of DNA that help produce working molecules, including proteins. A mutation is a change in the DNA sequence; other alterations include extra gene copies or genes joined together as a fusion.
- Proteins and receptors
- Proteins perform cellular jobs. A receptor is a signal-receiving protein, often on the cell surface. Some receptors activate a chain of signals inside the cell when they receive a message.
- Growth signalling and cell division
- Normal cells coordinate growth with signals, repair systems and checkpoints. Cancer cells can acquire changes that keep growth signals active or weaken the systems that normally restrain division.
- Cancer-driving alterations
- A driver helps cancer develop or survive. Many other changes are passengers and are not the main reason the cancer grows. More than one driver or escape route can be present.
- Oncogene addiction
- Some cancers rely heavily on an overactive growth gene—like a machine depending on one faulty master switch. Blocking that switch can be effective, but a tumour is a changing population of cells, not a simple electrical circuit.
- Resistance pathways
- A tumour may change the target, activate an alternative route or select cells that were already resistant. Blocking one route does not always block the whole network.
1. Instructions change
A gene alteration can change the amount or activity of a protein.
2. Growth stays active
A receptor or internal protein keeps sending a growth message.
3. Cells multiply
The altered signal supports survival and uncontrolled division.
For example, an EGFR mutation may keep a receptor active without the normal external signal. An EGFR inhibitor can reduce that activity. If another pathway later carries the growth message, the original drug may become less effective. See response and resistance.
Targeted therapy versus chemotherapy versus immunotherapy
| Feature | Targeted therapy | Chemotherapy | Immunotherapy |
|---|---|---|---|
| Mechanism | Interferes with a defined protein or pathway. | Damages DNA or disrupts division through various mechanisms. | Helps immune activity recognise or attack cancer; mechanisms vary. |
| Patient selection | Cancer type, stage, target, prior treatment and health. | Cancer type, stage, expected sensitivity and fitness. | Cancer type, stage, immune context, biomarkers and health. |
| Biomarkers | Often required, but not for every drug. | Usually not a matching mutation; selected tests still affect choice or safety. | Sometimes PD-L1, MSI/MMR or other markers; not universal. |
| Administration | Tablets, capsules, IV antibodies; some injectable formulations. | IV, oral or other routes depending on regimen. | Often IV for checkpoint inhibitors; other platforms differ. |
| Toxicities | Drug-specific rash, diarrhoea, blood-count, liver, cardiovascular or lung effects. | Regimen-specific nausea, low counts, neuropathy, mouth sores or hair loss. | Checkpoint inhibitors may inflame healthy organs. |
| Duration | Fixed course, maintenance or ongoing while beneficial and tolerated. | Fixed cycles or continued treatment depending on purpose. | Fixed course or continued treatment depending on regimen. |
| Resistance | Target changes, bypass signalling and other mechanisms. | Cancer cells may repair damage, expel drugs or survive through other mechanisms. | Cancer may evade recognition or suppress the immune response. |
| Monitoring | Symptoms, blood tests, scans and drug-specific heart, blood pressure or other checks. | Symptoms, counts, organ function and response assessment. | Symptoms, organ-function tests, scans and immune-toxicity assessment. |
Combinations may be appropriate because the treatments act differently. Read the Chemotherapy Master Guide and Immunotherapy Master Guide, or return to Cancer Treatment Explained.
Main types of targeted cancer medicines
- Small-molecule inhibitors
- These medicines can act inside cells and are often oral. Tyrosine kinase inhibitors (TKIs) are a major subgroup that blocks enzymes involved in signalling, such as EGFR or ALK.
- Monoclonal antibodies
- These laboratory-produced proteins bind specific targets, often on the cell surface or in the circulation. They may block receptors, neutralise signals or recruit immune activity. Not all antibodies work alike: checkpoint antibodies are usually discussed as immunotherapy.
- Anti-angiogenic medicines
- Antibodies or kinase inhibitors interfere with blood-vessel growth signals such as VEGF. They may affect several pathways and usually do not require a matching tumour mutation.
- PARP inhibitors
- These disrupt DNA-repair processes and can exploit selected weaknesses in a cancer’s repair system.
- CDK4/6 inhibitors
- These slow a key cell-cycle transition and are commonly paired with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer.
- BRAF/MEK and other pathway inhibitors
- Some regimens block two points in a growth pathway. Other established targets include RET, MET, NTRK, FGFR, IDH, KIT and BCR::ABL1; each has its own testing and treatment rules.
Antibody–drug conjugates (ADCs) are a related but distinct platform: an antibody is attached to a cell-killing payload through a linker. Binding to a target helps deliver the payload, but healthy tissues can still be affected. ADCs such as trastuzumab deruxtecan are not equivalent to an unconjugated antibody such as trastuzumab. Their eligibility and risks differ.
Why is molecular testing important?
Two people can have a cancer in the same organ but different biological drivers. Testing helps identify a treatment that is more likely to work, avoid ineffective choices and sometimes recognise an inherited risk. The right test is the one that answers a relevant clinical question; a larger panel is not automatically better.
- Histopathology
- A pathologist examines tissue structure and cells to establish the diagnosis. This is the foundation: molecular findings cannot always establish the cancer type on their own.
- Immunohistochemistry (IHC)
- Stains show selected proteins in tissue—for example HER2 or hormone receptors. IHC is often quick and preserves tissue architecture, but interpretation and validated scoring matter. Protein expression is not the same as a gene mutation.
- PCR
- A focused method that detects specified DNA or RNA changes. It can be sensitive and fast, but generally finds only what the assay was designed to look for.
- FISH / in situ hybridisation
- Fluorescent or other probes assess selected gene rearrangements or extra gene copies. It answers a defined question, rather than surveying all genes.
- Next-generation sequencing (NGS)
- A panel examines many genes together. DNA and RNA panels have different strengths; RNA testing may improve detection of some fusions. Coverage, tumour content, assay quality and interpretation limit what any panel can detect.
- Tissue biopsy
- Allows diagnosis, protein testing and molecular testing from the sampled site. Small samples, prior processing and variation between tumour sites can limit results. A repeat biopsy has risks and needs a clear purpose.
- Liquid biopsy and ctDNA
- A blood test may detect circulating tumour DNA shed by cancer cells. It can be useful when tissue is insufficient or to investigate resistance. Some cancers shed very little DNA, so a negative result does not exclude an alteration. Blood-cell changes can also complicate interpretation; tissue remains important for diagnosis and suspected transformation.
Read Cancer Biomarkers & Precision Oncology for the broader testing guide. Ask which test, sample and result will actually change the plan.
What is an actionable mutation?
- Driver versus passenger
- A driver contributes to cancer growth; a passenger accompanies the cancer without necessarily driving it. A driver is not automatically druggable.
- Actionable alteration
- A finding that can meaningfully guide care in that cancer and clinical setting. It may support an approved medicine, a guideline-supported option or a clinical trial. These levels of evidence are different.
- Predictive versus prognostic
- A predictive biomarker helps estimate benefit or lack of benefit from a particular treatment. A prognostic biomarker provides information about likely disease behaviour, regardless of a particular treatment. One marker can have both roles.
- Resistance alteration
- A molecular change that helps cancer survive a drug. Its meaning depends on which medicines have already been used and what other changes are present.
- Somatic versus germline
- Somatic changes arise in tumour cells and are usually not inherited. Germline changes are present from birth and can have implications for relatives. A tumour result suggesting an inherited change needs appropriate confirmatory testing and genetic counselling.
- Variant of uncertain significance (VUS)
- A change whose meaning is unclear. A VUS should not be treated as proof of an effective drug target or an inherited cancer syndrome.
The gene name alone is insufficient: the exact alteration, cancer type, stage, prior treatment and evidence all matter. A laboratory list of possible drugs is a starting point for clinical interpretation, not a prescription.
What if molecular testing is negative?
- The cancer may have no currently targetable alteration; chemotherapy, endocrine therapy, immunotherapy, surgery or radiotherapy may still be effective in the right setting.
- The assay may not cover the relevant change, the sample may contain too few cancer cells, or the tumour may shed too little DNA into blood.
- After a negative liquid biopsy, tissue testing may be appropriate if finding a target would change treatment and tissue can be obtained safely.
- Selected patients may benefit from additional or repeat testing after progression, an inadequate sample or a new clinically relevant question. Repeating NGS routinely in every patient is not necessary.
A negative result is not a statement that the cancer is untreatable. Ask what the test could detect and whether another test would meaningfully change care.
EGFR-targeted therapy
EGFR is a growth-signal receptor. In some non-small cell lung cancers (NSCLC), an activating mutation keeps its internal signalling machinery switched on. Common sensitising changes include exon 19 deletions and L858R. Exon 20 insertions are a different group and should not be assumed to respond like these common mutations.
Testing and treatment examples
Validated tissue or plasma PCR/NGS identifies the exact mutation. A negative plasma result may need tissue assessment. EGFR protein staining alone does not establish eligibility for a lung-cancer EGFR TKI.
Osimertinib is used in defined EGFR-mutated lung-cancer settings, including selected earlier-stage and advanced disease. Gefitinib, erlotinib, afatinib and dacomitinib are other examples with differing activity and indications. Amivantamab, an EGFR/MET-directed antibody, is used in particular lung-cancer regimens, including selected exon 20 insertion disease. Treatment may include chemotherapy or another targeted agent when evidence supports the combination.
Important side effects
Rash, diarrhoea, dry skin, mouth and nail problems are common with several agents. Lung inflammation can be serious. Osimertinib can affect cardiac function and the QT interval; antibody regimens can cause infusion reactions, and some combinations increase clot risk. Monitoring is medicine-specific.
Resistance and limitations
Secondary alterations such as T790M after some earlier TKIs, C797S in certain settings, MET amplification, or transformation to another cancer type can affect the next choice. In colorectal cancer, cetuximab or panitumumab selection usually depends on extended RAS status and the clinical context, including tumour side—not a lung-type EGFR mutation. RAS wild-type status does not guarantee benefit. Defined KRAS G12C inhibitor–antibody combinations are a separate exception to the usual RAS-based rule. Cetuximab also has uses in selected head-and-neck cancers.
ALK-targeted therapy
An ALK rearrangement joins part of ALK to another gene, making a fusion protein that drives growth in a subset of lung cancers. This differs from simply having an ALK gene or a nonspecific mutation.
Testing and treatment examples
Validated ALK IHC, FISH or molecular sequencing can identify the relevant rearrangement; the laboratory and clinical context determine whether confirmation is needed.
Alectinib, brigatinib and lorlatinib are important ALK inhibitors. Crizotinib, ceritinib and other agents have setting-specific roles. Some newer inhibitors reach the central nervous system (CNS) and can treat or delay brain involvement. Alectinib also has an adjuvant role in appropriately selected resected ALK-positive NSCLC.
Important side effects
Liver abnormalities, swelling, bowel symptoms and slow heart rate can occur with particular medicines. Alectinib may cause muscle toxicity; brigatinib can cause early pulmonary reactions and hypertension. Lorlatinib can raise cholesterol and triglycerides and affect thinking, mood or speech. Report changes promptly.
Resistance and limitations
Different secondary ALK alterations and bypass pathways can cause resistance. Brain activity varies between drugs and does not remove the need for brain imaging or local treatment when indicated. Choice depends on prior ALK therapy, disease distribution, safety and access.
ROS1-targeted therapy
ROS1 rearrangements create an abnormal signalling protein in a small subset of NSCLC. ROS1 and ALK are different targets even though some drugs inhibit both.
Testing and treatment examples
Molecular testing, often including RNA-based fusion analysis, or appropriate FISH can identify a ROS1 fusion. IHC may be a screening test requiring molecular confirmation.
Examples include crizotinib, entrectinib, repotrectinib and taletrectinib in relevant advanced lung-cancer settings. These drugs block ROS1 signalling. CNS activity and activity against resistance changes vary. For a dated regulatory example, the US FDA approved taletrectinib for adults with locally advanced or metastatic ROS1-positive NSCLC on 11 June 2025.
Important side effects
Depending on the agent, dizziness, balance problems, taste changes, bowel symptoms, liver abnormalities, oedema, heart effects or lung inflammation can occur. New neurological symptoms need assessment rather than being assumed to be a harmless drug effect.
Resistance and limitations
Acquired ROS1 changes, such as G2032R, or alternative pathways can reduce sensitivity. A drug active against one resistance alteration may not cover another. Prior treatment and current local approval determine which option is appropriate.
HER2-targeted therapy
HER2 (ERBB2) is a growth receptor. Amplification means extra gene copies; overexpression means excess protein; an activating mutation changes its function. These are related but non-interchangeable findings. HER2-directed treatment is relevant to selected breast, gastric/GE-junction and other cancers.
Testing and treatment examples
IHC assesses protein expression; ISH/FISH can assess amplification, especially for equivocal results. NGS can detect activating mutations. Scoring and eligibility differ by organ: breast scoring should not simply be applied to gastric cancer.
Trastuzumab and pertuzumab are antibodies; tucatinib is a kinase inhibitor used in specific combinations. Trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) are ADCs with different payloads, indications and safety profiles. Regimens depend on cancer type, stage and previous treatment.
Important side effects
Cardiac function may need monitoring with HER2 therapies. Diarrhoea and liver abnormalities occur with certain agents. T-DM1 may lower platelets. T-DXd can cause potentially fatal interstitial lung disease/pneumonitis as well as nausea and low counts: new cough or breathlessness needs urgent review.
Resistance and limitations
Loss or variation of HER2 expression, altered signalling and other escape routes can cause resistance. HER2-low (IHC 1+ or IHC 2+/ISH-negative) and HER2-ultralow (IHC 0 with membrane staining in the relevant test context) are selection concepts for particular ADC indications, not conventional HER2-positive disease. For example, a January 2025 US FDA indication for T-DXd covered eligible HR-positive metastatic HER2-low/ultralow breast cancer after endocrine progression. This does not make all HER2-low tumours eligible for all HER2 medicines.
BRAF and MEK inhibitors
BRAF and MEK are links in the MAPK growth-signalling pathway. Certain BRAF V600 alterations keep this pathway active. The exact variant matters; a non-V600 change should not be treated as interchangeable.
Testing and treatment examples
Validated PCR or NGS identifies a BRAF alteration; the cancer diagnosis and exact variant determine its significance.
Dabrafenib plus trametinib and encorafenib plus binimetinib are BRAF/MEK combinations used in defined settings, including selected melanoma and lung cancers. Dabrafenib/trametinib also has roles in selected thyroid cancers and certain tumour-agnostic settings. Dual blockade can suppress signalling more effectively than blocking one point.
Important side effects
Fever, chills, rash, fatigue and gastrointestinal symptoms may occur; heart dysfunction, eye problems, bleeding and other serious effects require specific monitoring. Fever can reflect treatment or infection and should be reported according to the team’s plan.
Resistance and limitations
Bypass signalling and new pathway changes can restore growth. BRAF V600E colorectal cancer often reactivates signalling through EGFR, so it needs a different strategy, such as encorafenib with cetuximab, with chemotherapy in appropriate settings. The US FDA approved encorafenib/cetuximab with fluorouracil-based chemotherapy in February 2026. A tumour-agnostic BRAF indication is not a licence to use the same regimen for every BRAF-mutated cancer; colorectal exclusions and other label conditions matter.
KRAS-targeted therapy
KRAS relays growth signals inside cells. G12C is one particular alteration; G12D, G12V and other KRAS mutations have different chemistry and treatment implications.
Testing and treatment examples
PCR or NGS must identify the exact KRAS variant. A report saying only “KRAS positive” is insufficient for choosing a G12C inhibitor.
Sotorasib and adagrasib inhibit KRAS G12C in specified advanced-cancer settings. US approvals include previously treated KRAS G12C-mutated advanced NSCLC. In colorectal cancer, approved examples include sotorasib with panitumumab and adagrasib with cetuximab after specified prior chemotherapy. EGFR blockade helps counter feedback signalling in this setting.
Important side effects
Diarrhoea, nausea, fatigue and liver injury are relevant. Pneumonitis can occur; adagrasib can prolong QT. Combining with an EGFR antibody adds skin toxicity, electrolyte and infusion-reaction risks. Liver monitoring and interaction checks are important, including after previous immunotherapy.
Resistance and limitations
New KRAS changes, additional gene alterations or bypass pathways can defeat treatment. These medicines are not interchangeable across KRAS variants. Broader RAS and other mutation-specific approaches are developing; a trial result does not itself establish approval or routine use. Ask whether a proposed use is locally approved, guideline-supported off-label care or investigational.
PARP inhibitors
PARP proteins help manage DNA damage. BRCA1/BRCA2 and related systems support accurate repair through homologous recombination. If a cancer already has a repair weakness, blocking PARP can create damage it cannot tolerate—an example of “synthetic lethality.” HRD describes a repair-deficient state, but tests and definitions differ.
Testing and treatment examples
Testing may include germline BRCA testing, tumour BRCA/other repair genes, or a validated HRD assay. Requirements differ by cancer, treatment line, combination and jurisdiction. A germline finding may also warrant genetic counselling for family implications.
Olaparib, niraparib, rucaparib and talazoparib have specific uses. Examples include selected ovarian maintenance settings, BRCA-associated HER2-negative breast cancer, selected prostate cancer and maintenance olaparib for eligible germline BRCA-mutated metastatic pancreatic cancer after platinum control. These are not class-wide approvals for every listed drug or cancer.
Important side effects
Anaemia, low platelets, other low blood counts, nausea and fatigue are important. Some drugs have additional risks, such as hypertension with niraparib. Rare myelodysplastic syndrome or acute myeloid leukaemia requires attention to persistent abnormal counts. Baseline and ongoing blood tests are essential.
Resistance and limitations
Restoration of DNA repair, including BRCA reversion changes, can lead to resistance. Not every HRD-positive cancer responds, and repair-gene findings do not all predict equal benefit. Some PARP indications have been restricted or withdrawn; use the current local label rather than an older broad indication list.
CDK4/6 inhibitors
CDK4 and CDK6 help cells move through the cell cycle toward DNA replication. Blocking them can slow growth in hormone receptor-positive, HER2-negative breast cancer. This generally relies on functioning downstream cell-cycle controls.
Testing and treatment examples
Selection usually uses ER/PR and HER2 pathology, stage, recurrence risk and prior treatment—not a routine CDK mutation test.
Palbociclib, ribociclib and abemaciclib are often combined with endocrine therapy because hormone signals and cell-cycle activity are connected. They are used in advanced disease; selected ribociclib and abemaciclib regimens also have early-stage roles. These drugs and indications are not interchangeable. Ovarian suppression may be needed with endocrine treatment in premenopausal patients.
Important side effects
Neutropenia is especially relevant with palbociclib and ribociclib. Diarrhoea is particularly important with abemaciclib. Liver abnormalities can occur; ribociclib requires attention to QT prolongation, electrolytes and interacting medicines. Abemaciclib carries venous-clot risk. Rare serious lung inflammation is recognised across the class.
Resistance and limitations
Cancer can bypass cell-cycle blockade or become resistant to the endocrine component. Blood counts, liver tests and drug-specific monitoring guide safe use. A dose adjustment directed by the oncology team does not automatically mean treatment has failed.
Anti-angiogenic targeted therapy
Tumours can release VEGF and other signals that help blood vessels grow. Anti-angiogenic medicines interfere with this support system, though tumours can use several routes to maintain a blood supply.
Testing and treatment examples
Selection usually rests on cancer type, treatment setting and safety assessment; a tumour mutation test is not necessarily required. Blood pressure, urine protein and bleeding or surgical history are important.
Bevacizumab is an antibody against VEGF. VEGFR-targeted kinase inhibitors include axitinib, sunitinib, pazopanib, lenvatinib and cabozantinib, which differ in their additional targets. Selected colorectal, ovarian, kidney, liver, thyroid and other cancer settings use particular drugs or combinations—not all of these agents for all of these cancers.
Important side effects
Hypertension, proteinuria, bleeding, arterial or venous clots and poor wound healing can occur. Some medicines can cause bowel perforation/fistula, heart effects, diarrhoea or hand-foot skin problems. Severe abdominal pain or major bleeding needs emergency assessment.
Resistance and limitations
Tumours can activate other vessel-growth signals or adapt to reduced oxygen. Uncontrolled hypertension, certain bleeding risks or recent surgery may affect eligibility. The team must coordinate treatment around operations, dental procedures and wound healing; interruption intervals depend on the drug and procedure.
Other important targeted pathways
RET
RET fusions drive selected lung and thyroid cancers; RET mutations are relevant in medullary thyroid cancer. NGS or other validated molecular testing distinguishes these findings. Selpercatinib blocks RET signalling in defined tumour-specific and some tumour-agnostic settings. Hypertension, liver abnormalities and QT effects need monitoring. Secondary RET changes or bypass pathways can cause resistance; a RET mutation is not the same as a fusion.
MET exon 14 skipping
This change prevents normal turnover of the MET receptor, allowing prolonged signalling in selected NSCLC. DNA/RNA testing must be able to detect the alteration. Capmatinib and tepotinib are examples. Oedema, liver injury and pneumonitis are important risks. MET amplification is a different finding with its own evidence thresholds. Secondary MET changes or alternative pathways can limit response.
NTRK fusions
A fusion involving NTRK1, NTRK2 or NTRK3 may drive cancers in different organs. RNA-capable NGS or other validated fusion testing is often important; screening protein stains may need confirmation. Larotrectinib, entrectinib and repotrectinib have defined tumour-agnostic uses. Neurological effects and liver toxicity vary by drug. NTRK point mutations alone do not establish the same eligibility; acquired kinase changes can cause resistance.
FGFR alterations
FGFR proteins transmit growth signals. FGFR2 fusions/rearrangements in selected bile-duct cancers can support pemigatinib or futibatinib; susceptible FGFR3 alterations in selected urothelial cancers can support erdafitinib. Molecular testing identifies the exact change. High phosphate, nail/skin changes and retinal problems require laboratory and eye monitoring. New visual symptoms need prompt assessment. Secondary FGFR changes or bypass signalling may cause resistance; not every FGFR alteration is an eligible target.
IDH1 and IDH2
Mutant IDH enzymes make an abnormal metabolite that can interfere with cell maturation. Validated mutation testing guides treatment. Ivosidenib targets IDH1 in defined blood-cancer and cholangiocarcinoma settings; enasidenib targets IDH2 in selected AML. These are not interchangeable. Differentiation syndrome in blood cancers can cause fever, swelling and breathlessness and needs urgent care; other risks include liver or heart-rhythm effects depending on the drug. Additional mutations or altered cell biology can cause resistance.
KIT and PDGFRA
These growth-receptor genes commonly drive gastrointestinal stromal tumours (GIST). Mutation testing complements diagnostic IHC and predicts sensitivity. Imatinib treats many susceptible GISTs, but PDGFRA D842V is typically imatinib-resistant; avapritinib is an option in its defined setting. Oedema, nausea and blood-count/liver effects vary; avapritinib can cause cognitive effects and serious bleeding. Secondary mutations can require another inhibitor. Stage, recurrence risk and exact genotype govern use.
Other established targets
BCR::ABL1 testing identifies the fusion driving CML and some ALL; drugs such as imatinib or other BCR::ABL1 inhibitors have disease-specific roles, with molecular monitoring. BTK inhibitors and the BCL2 inhibitor venetoclax are used in selected blood cancers; mutation testing is not always the selection test. Bleeding/heart-rhythm effects with some BTK inhibitors and tumour lysis with venetoclax require preventive plans. PIK3CA/AKT-pathway and mTOR inhibitors also have selected breast-cancer or other roles; mutation requirements and risks such as high glucose, rash or mouth ulcers depend on the medicine. These examples are not a prescribing list.
Tumour-specific means the indication is linked to a particular cancer. Tumour-agnostic means a biomarker can guide treatment across several organs, but age, stage, prior treatment, resistance and other eligibility rules still apply. Neither term guarantees benefit.
How is targeted therapy given?
Many small-molecule medicines are tablets or capsules taken at home, once or more than once daily. Some are continuous; others have planned treatment-free days. Antibodies are often intravenous infusions given at a day-care unit, and some products have subcutaneous formulations. A tablet is still an anticancer medicine and requires supervision.
- Use the exact dose, schedule and food instructions for the prescribed product. Do not crush or open medicines unless the pharmacist confirms that it is safe.
- Keep a treatment calendar and an up-to-date medication list; plan refills before supplies run out.
- Infusions may need premedication and observation for reactions. Tell the nurse immediately about breathing difficulty, flushing, chest discomfort or dizziness.
- Drug interactions can change exposure and effectiveness. Ask about every new prescription, over-the-counter medicine or supplement.
- Duration depends on the drug and treatment goal. Feeling better is not a reason to stop on your own.
What happens before starting targeted therapy?
The team confirms the diagnosis, stage, relevant biomarker and intended benefit, then balances treatment against health conditions, previous toxicity and personal priorities. Ask whether the aim is to reduce recurrence risk, shrink disease, maintain control or relieve symptoms.
- Confirm that the test result is adequate, relevant and linked to this particular regimen.
- Review all medicines, supplements, allergies and previous anticancer treatments.
- Check blood counts, kidney and liver function, with electrolytes and other tests as the drug requires.
- Record blood pressure; obtain ECG, echocardiography or other cardiac assessment when indicated. Not everyone needs every test.
- Discuss pregnancy testing when relevant, contraception, fertility preservation and breastfeeding.
- Obtain baseline imaging and a clear response-assessment plan; arrange brain imaging when the cancer and setting warrant it.
- Address infection risks, vaccination or viral screening where relevant to the regimen, planned surgery and wound healing.
- Provide written instructions for side effects, missed doses, monitoring appointments and daytime/out-of-hours contact numbers.
Common side effects
There is no single targeted-therapy side-effect profile. Some patients have few problems; others develop serious toxicity. The medicine, dose, combination, organ function and other illnesses all matter. Symptoms can come from the cancer, infection or another illness as well as treatment.
- Skin, nails and mouth
- Acne-like rash, dryness, nail-fold inflammation, hand-foot symptoms and mouth ulcers occur with particular agents. Early reporting can prevent worsening.
- Bowel symptoms and fatigue
- Diarrhoea can lead to dehydration; persistent fatigue may reflect anaemia, poor intake or another treatable cause. Report changes that interfere with daily activities.
- Blood counts and infection
- Some drugs reduce red cells, platelets or infection-fighting cells. Bruising, breathlessness, fever or chills require assessment. Regular blood tests may detect problems before symptoms develop.
- Liver and kidney effects
- Liver enzymes may rise without symptoms. Some drugs cause protein loss in urine or kidney injury. Jaundice or substantially reduced urine needs urgent review.
- Blood pressure, oedema and heart effects
- Hypertension, swelling, weakened heart pumping or rhythm abnormalities occur with selected agents. Monitoring may include home blood pressure, ECG or an echocardiogram.
- Lung inflammation
- Pneumonitis can occur with several targeted medicines and ADCs. New cough, breathlessness or reduced oxygen needs urgent assessment, even when mild initially.
Ask for the few most important risks of your own medicine. Do not use the severity of side effects to judge whether treatment is working. A planned dose change can improve safety while maintaining useful treatment exposure.
EGFR inhibitor skin toxicity
EGFR helps maintain normal skin as well as participating in cancer signalling. Inhibiting it can cause an acneiform—acne-like—rash, often on the face, scalp or upper body. It is not ordinary teenage acne and is not caused by poor hygiene. Dry, cracked skin and painful inflammation around nails can develop later.
- Use gentle cleansing, a bland fragrance-free moisturiser and broad-spectrum sun protection, including clothing and shade.
- Avoid harsh acne products, scratching, picking and irritating nail treatments. Keep nails short without injuring the skin around them.
- Tell the team early about a painful, spreading or bothersome rash. The team may prescribe preventive or treatment medicines. Do not self-prescribe antibiotics or steroid creams/tablets.
- Seek prompt assessment for pus, fever, painful nail swelling or rash affecting daily activity. Blistering, peeling, skin pain or mouth/eye involvement needs urgent care.
Rash may accompany the drug’s biological activity, but its presence or absence does not reliably measure the response in an individual patient. Do not increase a dose to produce a rash.
Evidence: [31].
Diarrhoea during targeted therapy
Some medicines cause diarrhoea early; it may also occur later or reflect infection or another cause. Ask for a drug-specific action plan before treatment. Record how often stools occur compared with normal and whether there is blood, fever, pain or dizziness.
Use frequent fluids or oral rehydration as advised; patients with fluid restrictions, heart failure or kidney disease need individual guidance. Contact the team promptly for new persistent diarrhoea, and urgently for severe/frequent stools, inability to drink, reduced urine, faintness, blood in stool, fever or severe abdominal pain. Do not wait for the next appointment.
Use anti-diarrhoeal medicine only according to the agreed plan. Do not improvise dose reductions or prolonged interruptions. Some drugs require an immediate hold for significant toxicity: follow your written instructions and contact the team urgently for advice about the next dose. Severe symptoms require emergency care, not waiting for permission.
Serious warning signs
KEEP THIS INFORMATION ACCESSIBLE
Emergency assessment now
- Severe or rapidly worsening breathlessness, chest pain, fainting or collapse.
- Uncontrolled/significant bleeding, vomiting blood or black stools.
- Sudden severe headache, new weakness, confusion, seizures or other acute neurological symptoms.
- Blistering/peeling rash, painful widespread skin changes, or swelling that affects breathing.
- Severe abdominal pain, profound dehydration or rapid deterioration.
Contact oncology urgently / seek urgent assessment
- Any new or worsening cough or breathlessness, even before it becomes severe.
- Persistent or severe diarrhoea, repeated vomiting, inability to keep fluids down, or markedly reduced urine.
- Jaundice, dark urine, major new swelling or new vision problems.
- Fever of 38°C (100.4°F) or more, shaking chills or signs of infection—especially with low counts or combination chemotherapy. Follow any more cautious threshold in your own treatment plan.
If the team cannot be reached promptly, seek urgent medical care. Use emergency services for severe symptoms and do not drive yourself if seriously unwell. Tell clinicians the exact drug names and last dose dates. These examples do not cover every medicine-specific emergency.
Keep the oncology daytime and out-of-hours numbers, treatment list and nearest emergency department details together. This website is not an emergency contact service. Follow the prescribed emergency/hold instructions rather than making an unsupervised long-term treatment change.
How do doctors know targeted therapy is working?
Assessment combines symptoms, examination and appropriate tests. CT or MRI commonly measures disease. PET-CT is useful in selected cancers and situations, not automatically at every assessment. Tumour markers can help in particular diseases but rarely replace imaging or clinical assessment.
Molecular monitoring is established in some diseases—for example BCR::ABL1 measurements in CML. Routine ctDNA monitoring is not an interchangeable substitute for scans in every solid tumour. The timing of tests depends on the cancer, drug and treatment goal.
- Partial response
- The measurable cancer has shrunk enough to meet the applicable response criteria.
- Stable disease
- There is neither sufficient shrinkage for a partial response nor sufficient worsening for progression. Stability can be a meaningful benefit.
- Complete response
- No disease is detectable by the assessment method. This does not always mean cure or absence of microscopic cancer.
- Progression
- Cancer has grown or new disease has appeared according to the relevant assessment. The team considers the whole pattern, symptoms and reliability of the findings.
After surgery, there may be no measurable tumour; the goal may be reducing future recurrence rather than demonstrating shrinkage. Your oncologist should explain what “working” means in that setting.
Why does targeted therapy sometimes stop working?
Primary resistance means a cancer does not respond adequately from the start. The detected target may not be its main dependency, another pathway may dominate, or other biological features may prevent benefit. Acquired resistance means a cancer that was controlled later finds ways to survive.
- The target changes
- A secondary mutation can change where a drug binds—like changing a lock so the same key fits poorly. The actual chemistry is more complex, and not every new mutation has another effective drug.
- Bypass signalling
- Another pathway carries the growth message. For example, increased MET signalling can contribute to resistance in some EGFR-driven lung cancers.
- Tumour heterogeneity
- Different cells and tumour sites can contain different alterations. Treatment may suppress sensitive cells while a resistant population becomes more prominent.
- Histological transformation
- A cancer can change its cell type, such as selected EGFR-mutated lung cancers transforming to small-cell cancer. A tissue biopsy may be needed because blood sequencing cannot establish tissue architecture.
- Drug exposure and adherence
- Interactions, absorption problems, missed doses or dose-limiting toxicity can reduce effective exposure. This is assessed without blame and does not mean every progression is caused by missed tablets.
- Protected sites and changing biology
- Drug penetration can vary between body sites, including the brain. A small area of progression may differ from widespread resistance.
Target blocked
Sensitive cells slow down or die.
Escape route survives
A changed target or alternative signal supports some cells.
Resistant cells expand
One site or several sites can begin growing again.
Resistance reflects cancer evolution and treatment limitations. It is not a personal failure. Some people have long periods of control; others need a different plan much sooner.
What happens when targeted therapy stops working?
- Confirm the pattern and extent of progression and assess symptoms, organ function, treatment exposure and the patient’s priorities.
- Consider a repeat tissue biopsy when it is safe and likely to change management, especially if transformation is suspected.
- Use liquid biopsy or repeat molecular testing selectively to look for a resistance mechanism. A negative blood test may not settle the question.
- Switch to a suitable targeted drug, use an evidence-supported combination, or change to chemotherapy, endocrine treatment or another appropriate approach.
- Immunotherapy is an option in some settings, but it is not automatically the best next treatment for every driver-positive cancer. Prior targeted therapy and sequencing can also affect toxicity.
- For limited progression, local treatment such as radiotherapy while continuing the effective systemic drug may be reasonable in selected cases; this requires an individual decision.
- Discuss clinical trials and supportive/palliative care. Symptom relief and quality-of-life support can be provided alongside anticancer treatment.
Do not stop a working component or combine drugs independently. The safest next step depends on the cancer, resistance mechanism, distribution of disease and overall condition.
Can targeted therapy cure cancer?
Some targeted treatments contribute to curative-intent care—for example, selected treatment before or after definitive local therapy. Others can support very long disease control in particular cancers. Neither a biomarker match nor a complete scan response guarantees cure.
In many metastatic cancers, the usual aim is to control disease, improve symptoms and extend life. There is no single survival estimate for “targeted therapy”: prognosis depends on the cancer, stage, driver, sites involved, response, health and available subsequent treatment. Ask for a realistic range for your own situation rather than comparing with another patient.
How long is targeted therapy continued?
- Fixed-duration adjuvant treatment
- Some medicines are given for a defined course after surgery to reduce recurrence risk; the duration is specific to the drug and indication.
- Treatment while beneficial
- Many advanced-cancer regimens continue until progression, unacceptable toxicity or another clinical reason to change. Selected limited progression may be managed differently.
- Maintenance
- Treatment may continue after an initial response to help preserve control. Eligibility and stopping rules differ between regimens.
- Individual adjustments
- Toxicity, surgery, pregnancy planning or other circumstances may prompt a supervised hold, dose change or discontinuation. Do not apply another patient’s duration to your treatment.
Ask for the planned duration, assessment points and criteria for stopping in writing. There is no universal number of cycles or years.
Diet, supplements and targeted therapy
- Food can increase or reduce absorption depending on the medicine. Follow the exact with-food or empty-stomach directions; do not assume all tablets have the same instructions.
- Grapefruit and related products interact with certain drugs, not all targeted therapy. Ask the pharmacist about the prescribed medicine and local fruit/herbal products.
- Acid-suppressing medicines can reduce absorption of selected oral agents. Spacing doses does not solve every interaction; do not stop a necessary stomach medicine without an agreed alternative.
- Herbal remedies, St John’s wort, high-dose supplements and “immune boosters” may alter drug exposure or harm organs. Show the team the complete ingredient list.
- After a missed dose or vomiting, follow the drug-specific instructions. Do not automatically repeat the tablet or double the next dose. Contact the team/pharmacist if unclear.
- Store in the original packaging as directed, away from children, moisture and excess heat. Do not share medicines; ask how to return unused tablets safely.
A varied diet with adequate energy and protein supports recovery. Restrictive “anticancer diets” cannot replace treatment and may worsen nutrition. A dietitian can help if diarrhoea, mouth soreness, poor appetite or weight loss affects eating.
Work, travel and exercise
Many people continue some normal activities, but the level and pace depend on symptoms and treatment risks. Flexible work hours, planned rest and light activity can help. Exercise should be adapted to heart function, blood counts, bone involvement, balance and fitness; do not exercise through fever, chest pain or significant breathlessness.
Discuss travel before booking. Plan enough medicine, correct storage, time-zone dosing, monitoring appointments, a treatment letter and access to urgent care. Keep medicines in labelled packaging and check applicable travel rules. Avoid driving if a drug causes dizziness, visual disturbance or cognitive changes. Sun and infection precautions should match the actual regimen.
Fertility, pregnancy and breastfeeding
Many targeted medicines can harm a developing baby. Fertility effects, contraception requirements and the interval after treatment vary between drugs and apply to both women and men where specified. Some medicines reduce the reliability of hormonal contraception, so the method also needs checking.
Discuss fertility preservation before treatment when feasible, arrange pregnancy testing when indicated and tell the oncology team promptly about a possible pregnancy. Breastfeeding is often avoided during treatment and for a drug-specific interval afterwards. Do not use a single washout period for all medicines or stop treatment independently to conceive.
Targeted therapy in older patients
Age alone does not determine suitability. Functional status, frailty, nutrition, falls, memory, social support, comorbidities and personal goals matter. An oral drug is not automatically easier or safer than an infusion.
Polypharmacy increases interaction risks. Kidney or liver impairment may change dose selection or monitoring, and some drug-related changes in creatinine do not reflect the same mechanism as true kidney injury. The treating team should interpret results. Practical support with tablets, transport and symptom reporting can make treatment safer.
Financial considerations
Ask about the whole cost: testing, medicines, administration, monitoring, supportive treatment and travel. Discuss insurance or relevant assistance programmes before treatment starts and tell the team early if cost threatens adherence.
Quality-assured, regulator-approved generics may reduce the cost of small-molecule medicines. Biosimilars are rigorously assessed versions of biological medicines with no clinically meaningful differences in the approved comparison; they are not ordinary chemical generics. The exact product and approved use still matter.
Use licensed pharmacies and verified supply chains. Avoid unverified online products, repackaged tablets of uncertain origin and changing brand, strength or schedule without the team/pharmacist checking. Approval abroad does not automatically establish approval, availability or reimbursement in India.
Targeted therapy myths
Myth: Targeted therapy has no side effects.
Fact: Healthy tissues can share the target; serious drug-specific toxicity is possible.
Myth: Targeted therapy works for every cancer.
Fact: Benefit depends on biology and a proven clinical setting.
Myth: Every cancer mutation has a matching drug.
Fact: Many findings have no established treatment; some have uncertain significance.
Myth: Targeted therapy is always better than chemotherapy.
Fact: The appropriate choice depends on the cancer and goal; combination treatment may be best.
Myth: Targeted therapy is always a tablet.
Fact: Many targeted antibodies are infused, and some products are injected.
Myth: A liquid biopsy can always replace tissue biopsy.
Fact: Low DNA shedding can produce a negative result; tissue is often needed for diagnosis and transformation.
Myth: All patients require NGS.
Fact: Testing should answer a treatment-relevant question; focused tests may be sufficient.
Myth: If targeted treatment stops working, no options remain.
Fact: Reassessment may identify another drug, local treatment, chemotherapy or a trial; supportive care remains valuable.
Myth: Targeted therapy always cures cancer.
Fact: Some regimens support cure; many aim for control. Neither is guaranteed.
Myth: All HER2-positive cancers receive identical treatment.
Fact: Cancer site, stage, test pattern and previous treatment change the plan.
Myth: A positive biomarker guarantees response.
Fact: Other pathways, tumour variation and resistance can limit benefit.
Myth: Targeted drugs never affect healthy cells.
Fact: Their targets or related processes may also be important in normal organs.
Frequently asked questions
Will every patient with cancer need targeted therapy?
No. It is used when cancer biology and clinical evidence support it.
Does everyone need a large NGS panel?
No. The diagnosis, stage, available treatments and existing test results determine which tests are useful.
Is IHC the same as genetic sequencing?
No. IHC usually examines proteins; sequencing examines genetic material. Each answers different questions.
Can a blood test replace my biopsy?
Sometimes blood testing helps select a treatment, but tissue is often needed to establish the diagnosis and investigate transformation.
What does a negative liquid biopsy mean?
It may mean no detectable alteration, or insufficient tumour DNA in the blood. Ask whether tissue testing would change care.
Does a tumour mutation mean my children will inherit it?
Usually not. Tumour changes are often acquired. Suspected germline findings need appropriate confirmation and counselling.
Does a positive biomarker guarantee success?
No. It increases confidence only in the appropriate clinical setting; resistance and other biological factors still matter.
Why am I receiving chemotherapy as well?
A proven combination may control cancer more effectively than either approach alone in that setting.
Are tablets weaker than infusions?
No. Route does not determine anticancer strength or safety.
Will I lose my hair?
Some medicines cause thinning or changes; effects depend on the drug and any accompanying chemotherapy.
Does a rash mean treatment is working?
Rash alone cannot tell whether an individual cancer is responding. Scans and clinical assessment remain important.
Should I stop if I have diarrhoea?
Follow the written drug-specific action plan and contact the team. Severe symptoms require urgent assessment; avoid unsupervised dose changes.
What if I miss a tablet?
Use the medicine-specific instructions or ask the pharmacist. Do not automatically double the next dose.
What if I vomit after a tablet?
Do not automatically take another dose. Follow the particular drug’s instructions and seek advice if unclear.
Can I take antacids or acid-suppressing tablets?
Some interact substantially with selected medicines. Ask before starting, stopping or changing them.
Can I take herbal supplements?
Only after the team checks the ingredients for interactions and toxicity.
How soon will I know if it is working?
Symptoms may change before scans, but reliable assessment occurs on a planned schedule specific to the cancer and regimen.
Is stable disease a useful result?
Yes. Preventing growth can be a meaningful treatment benefit.
Does a complete response mean I can stop?
Not automatically. Undetectable disease is not always cure, and stopping rules are drug- and disease-specific.
Will treatment continue forever?
Some courses have fixed durations; others continue while useful and tolerable. Ask for your planned assessment and stopping points.
What happens if resistance develops?
The team reassesses disease and may use selected repeat testing, another treatment or a clinical trial.
Can I work or travel?
Often, with individual planning around symptoms, medicines, tests and access to care.
Are approved generics or biosimilars reasonable options?
They may improve affordability. Your oncology team and pharmacist should confirm the product, source and suitability.
Can I become pregnant or breastfeed during treatment?
Many drugs pose risks. Contraception, conception timing and breastfeeding require medicine-specific advice.
When should I seek urgent help?
New breathlessness, chest pain, fainting, major bleeding, severe diarrhoea, neurological symptoms, jaundice or fever may need urgent care. See the safety section and your own treatment plan.
Questions to ask your oncologist
- What biomarker or pathway is driving my cancer?
- Which test identified it, and is the result actionable in this cancer?
- What treatment is recommended, and is this use locally approved, guideline-supported or investigational?
- What benefit is realistically expected, and what is the treatment goal?
- What are the most important adverse effects and emergency warning signs?
- How will treatment and response be monitored?
- What food, medicine and supplement interactions should I avoid?
- What should I do after a missed dose, vomiting or diarrhoea?
- How long is treatment planned?
- What happens if resistance develops?
- Are alternative treatments or clinical trials available?
- What will testing and treatment cost, and are reliable lower-cost options available?
- Whom should I contact outside normal clinic hours?
A final message for patients and families
Targeted therapy represents an important advance in precision oncology, but the right treatment depends on the right cancer biology.
Not every patient requires targeted therapy, not every mutation has an effective drug, and no targeted medicine is free of risk.
Understanding biomarkers, treatment goals, side effects and resistance helps patients participate meaningfully in their care.
Explore the Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer guides for disease-specific context.
Medical Disclaimer
The information on Cancer Aware is provided for general education and awareness only. It is not a substitute for consultation, diagnosis or treatment by a qualified healthcare professional. If you have persistent, worsening or concerning symptoms, please seek medical advice.
Sources & Medical Review
Reference check: . This chapter is general education. Sources support the named mechanisms, testing principles and safety topics; the examples are not an exhaustive prescribing guide.
Approval, guidelines and research are different. Regulatory approval applies to a specific jurisdiction, population and regimen. Guideline-supported practice may sometimes be outside the local label. Investigational treatment is being evaluated and should not be presented as established care. US FDA examples here do not establish Indian approval or access. Indications can expand, narrow or be withdrawn; clinicians should check the current local prescribing information and applicable guidance before treatment.
- NCI — Targeted Therapy to Treat Cancer
- NCI — Biomarker Testing for Cancer Treatment
- NCI — Targeted Therapy Drug List by Cancer Type
- NCI — Non-Small Cell Lung Cancer Treatment (PDQ)
- FDA — Amivantamab for EGFR exon 20 insertion NSCLC (2024)
- FDA — Trastuzumab deruxtecan prescribing information (2025; consult current label for subsequent changes)
- FDA — HER2-low/ultralow breast cancer indication (January 2025)
- FDA — Sotorasib with panitumumab in KRAS G12C colorectal cancer (2025)
- FDA — Oncology/Hematologic Malignancies Approval Notifications
- DailyMed — Lorlatinib prescribing information
- FDA — Adjuvant alectinib in ALK-positive NSCLC (2024)
- FDA — Repotrectinib in ROS1-positive NSCLC (2023)
- FDA — Taletrectinib in ROS1-positive NSCLC (2025)
- NCI — Targeted Therapy for Breast Cancer
- NCI — Dabrafenib/trametinib for BRAF-positive cancers
- FDA — Encorafenib/cetuximab with chemotherapy in BRAF V600E colorectal cancer (2026)
- DailyMed — Adagrasib prescribing information
- NCI — Olaparib
- DailyMed — Olaparib prescribing information
- DailyMed — Niraparib prescribing information
- FDA — CDK4/6 inhibitor lung-inflammation safety communication
- FDA — Ribociclib safety and prescribing information
- FDA — Abemaciclib early breast cancer indication
- DailyMed — Bevacizumab prescribing information
- NCI — Angiogenesis Inhibitors
- FDA — Selpercatinib RET fusion-positive solid tumours (2026)
- FDA — Larotrectinib for NTRK fusion-positive solid tumours
- FDA — Erdafitinib in FGFR3-altered urothelial cancer
- FDA — Ivosidenib in MDS and differentiation-syndrome warning
- NCI — Gastrointestinal Stromal Tumours Treatment (PDQ)
- American Cancer Society — Targeted Therapy Side Effects
- NCI — Why Do Cancer Treatments Stop Working?
- NCI — Cancer Therapy Interactions with Foods and Dietary Supplements
- ASCO — Living Guideline: Stage IV NSCLC with Driver Alterations, 2026.3.2
- ESMO — Personalised Cancer Medicine: Guide for Patients
- FDA — Futibatinib trial and indication overview
- FDA — Pharmacogenomic Biomarkers in Drug Labelling
Medical Content & Review
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
Read the site-wide Sources & Medical Review information and Medical Disclaimer. References do not imply endorsement by any source organisation.